Defining A "Next-Gen" LNP

How can we define a “next-generation” LNP?

The rapid development, scale-up, and successful commercialization of mRNA vaccines served as a great case study on the important role mRNA/RNA therapeutics can play in society. However, for those striving to develop next-gen RNA therapeutics, achieving more specifically targeted non-viral delivery is a large hurdle to broadening these therapeutics’ applicability, durability, and effectiveness. 

On October 4, 2022 Bioprocess Online Live hosted a panel discussion digging into the scientific-, development-, and business-related advancements that will enable the RNA therapeutics industry to meet the needs of a broader array of patient populations.

In this segment, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, share their expectations on which scientific advancements/characteristics will be most important for LNP-delivery of mRNA/RNA cargo in the future.

View the full presentation on-demand here.


access the Video!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online